- News
- Announcements
Announcements
Current & archive
Horizon Scanning in Oncology - Fact Sheets
We are pleased to introduce you eight new Fact Sheets.
Fact Sheet No. 138 (August 2023)
Crisantaspase (Enrylaze®) for the treatment of acute lymphoblastic leukaemia (ALL) and lymphoblastic lymphoma (LBL)
Fact Sheet No. 139 (August 2023)
Cedazuridine/decitabine (Inaqovi®) for the treatment of newly diagnosed acute myeloid leukaemia (AML)
Fact Sheet No. 140 (August 2023)
Elacestrant (Orserdu®) monotherapy for the treatment of oestrogen receptor (ER)?positive, HER2-negative, locally advanced or metastatic breast cancer
Fact Sheet No. 141 (August 2023)
Talquetamab (Talvey®) for the treatment of adult patients with relapsed and refractory multiple myeloma (MM)
Fact Sheet No. 142 (August 2023)
Epcoritamab (Tepkinly®) as monotherapy for the treatment of relapsed or refractory diffuse large B-cell lymphoma (DLBCL)
Fact Sheet No. 143 (August 2023)
Tislelizumab (Tevimbra®) as monotherapy for the treatment of unresectable, locally advanced, or metastatic oesophageal squamous cell carcinoma (OSCC)
Fact Sheet No. 144 (August 2023)
Nivolumab (Opdivo®) as monotherapy for the adjuvant treatment of Stage IIB or IIC melanoma, or melanoma with involvement of lymph nodes or metastatic disease
Fact Sheet No. 145 (August 2023)
Pembrolizumab (Keytruda®) with trastuzumab, fluoropyrimidine and platinum-containing chemotherapy for the first-line treatment of locally advanced unresectable or metastatic HER2-positive gastric or gastro-oesophageal junction (GEJ) adenocarcinoma
Robot-assisted surgery in thoracic and visceral indications – Update 2023
Robotic-assisted surgery represents a technically advanced form of a minimally invasive procedure that claims to improve clinical outcomes as well as healthcare resource utilization. This report is an update of a systematic review from 2019, which examined the effectiveness and safety of robotic-assisted surgery in thoracic and visceral indications, compared to open surgery and conventional laparoscopy. In total, 14 indications were investigated, with no evidence identified for five indications. Due to the heterogeneous results and lack of evidence for some study endpoints, a general statement on the effectiveness and safety of robotic-assisted surgery is not possible.
Publication: HTA Project Report No. 108: https://eprints.aihta.at/1461
Contact : Nicole Grössmann-Waniek
Horizon Scanning in Oncology - Fact Sheets
We are pleased to introduce you three new Fact Sheets.
Fact Sheet No. 135 (July 2023)
Tremelimumab (Imjudo®) with durvalumab (Imfinzi®) and platinum-based chemotherapy for the first-line treatment of metastatic non-small cell lung cancer (NSCLC)
Fact Sheet No. 136 (July 2023)
Trifluridine / tipiracil (Lonsurf®, TAS-02) with bevacizumab for the treatment of metastatic colorectal cancer (CRC)
Fact Sheet No. 137 (July 2023)
Sacituzumab govitecan (Trodelvy®) for the treatment of unresectable or metastatic hormone receptor-positive, HER2-negative breast cancer
Evaluation of individual medical procedures - Reports 2023
We are pleased to introduce our new reports.
Decision Support Documents 2023:
- DSD 135: Percutaneous aspiration thrombectomy for pulmonary embolism https://eprints.aihta.at/1454/
- DSD 136: Transcranial magnetic resonance-guided high-intensity focused ultrasound treatment in patients with drug-resistant essential tremor https://eprints.aihta.at/1455/
- DSD 137: Bleomycin Electrosclerotherapy for Vascular Anomalies: Systematic Review https://eprints.aihta.at/1456/
- DSD 138: Electrical auricular vagus nerve stimulation for pain https://eprints.aihta.at/1457/
+ 3 Updates
- DSD 41: Percutaneous mitral valve repair with a clip device in patients with mitral regurgitation. 2nd Update 2023 https://eprints.aihta.at/1451/
- DSD 111: Allogeneic mesenchymal stem cells for Crohn's Disease-associated complex perianal fistulas. 1st Update 2023 https://eprints.aihta.at/1452/
- DSD 118: 177Lu-PSMA Radioligand Therapy in Patients with Metastatic Castration-Resistant Prostate Cancer: Systematic Review. 1st Update 2023 https://eprints.aihta.at/1453/
Horizon Scanning in Oncology - Fact Sheets
We are pleased to introduce you three new Fact Sheets.
Fact Sheet No. 130 (May 2023)
Glofitamab (Columvi®) as monotherapy for the treatment of relapsed or refractory (R/R) diffuse large B-cell lymphoma (DLBCL)
Fact Sheet No. 131 (May 2023)
Pirtobrutinib (JaypircaTM) as monotherapy for the treatment of relapsed or refractory (R/R) mantle cell lymphoma (MCL)
Fact Sheet No. 132 (May 2023)
Futibatinib (Lytgobi®) for the treatment of locally advanced or metastatic cholangiocarcinoma
Horizon Scanning in Oncology - Fact Sheets
We are pleased to introduce you two new Fact Sheets.
Fact Sheet No. 133 (May 2023)
Nivolumab (Opdivo®) in combination with platinum-based chemotherapy for the neoadjuvant treatment of resectable non-small cell lung cancer (NSCLC)
Fact Sheet No. 134 (May 2023)
Piflufolastat (18F) (Pylclari®) for the diagnosis of prostate cancer
Horizon Scanning in Oncology - Fact Sheets
We are pleased to introduce you one new Fact Sheets.
Fact Sheet No. 129 (April 2023)
Lisocabtagene maraleucel (Breyanzi®) for the treatment of diffuse large B-cell lymphoma (DLBCL), high grade B cell lymphoma (HGBCL), primary mediastinal large B-cell lymphoma (PMBCL) and follicular lymphoma grade 3B (FL3B)
Sponsoring of patient initiatives in Austria.5th Update of the Systematic Analyses 2014 to 2019
As patient initiatives expand their activities and continue to professionalise, their need for financial resources, which often gets bankrolled by pharma-ceutical companies, increases accordingly. To make these financial transactions more transparent, the pharmaceutical industry responded with volun-tary disclosure commitments. AIHTA (then still as LBI-HTA) systematical-ly analysed the content of these voluntary disclosures of sponsorship for pa-tient initiatives by members of the Association of Austria’s Pharmaceutical Industry (PHARMIG - Verband der pharmazeutischen Industrie Österreichs) for the first time in 2014 and aims to carry out regular and consistent moni-toring of these payments. The present fifth update systematically researched the extent of financial support to patient initiatives disclosed by member companies of PHARMIG for the fiscal year of 2021.
Publication: Policy Brief No. 007/5. Update: https://eprints.aihta.at/1443/
Contakt: Claudia Wild
Oral and parenteral preexposure prophylaxis (PrEP) to prevent HIV in people at risk: a systematic review of clinical effectiveness and safety with assessment of organisational, economic, patients/social, ethical and legal elements
Preexposure prophylaxis (PrEP) is an antiretroviral therapy-based HIV prevention strategy to prevent HIV infection in people who have not been infected with the virus but are at high risk of infection. The report aimed to provide an update evidence synthesis based on a systematic literature search regarding the effectiveness and safety of in the EU and/ or US approved oral and parenteral PrEP pharmaceutical to prevent HIV infection in populations at risk. Additionally, the report addressed organisational, economic, patient/social, ethical and legal aspects to support evidence-based decision-making process on PrEP in Austria.
Publication: HTA Project Report No. 152: https://eprints.aihta.at/1436/
Contact: Inanna Reinsperger
Update PET/PET-CT evidence for need based planning in the area of oncology
This report is based on that of the LBI-HTA of 2015 and the updates of 2018 and 2020. Various guideline databases and policies were searched to identify the recommended oncological indications for the use of PET/PET-CT applications. In addition to guideline databases, recommendations and non-recommendations from professional societies were considered.
The guideline search identified a total of 122 recommendations regarding the use of PET. The majority of the recommendations (n=112) resulted from the guideline search and database search of national professional societies. The search in supranational professional societies resulted in 10 recommendations. A further 36 recommendations were directed against the use of PET ("inappropriate" cancer indications).
The overall recommendations of the present 2023 update (as in the previous year's 2015 & 2018 reports, as well as the 2020 update) indicate little benefit from PET as a primary or standard diagnostic (not least because of radiation exposure). The summarised evidence from guidelines can be used as a guideline for investment decisions.
Publication: Policy Brief No. 003/3. Update: https://eprints.aihta.at/1442/
Contact: Claudia Wild
